Clinical data | |
---|---|
Pronunciation | /aɪˈdɛləlɪsɪb/ eye-DEL-ə-li-sib |
Trade names | Zydelig |
Other names | GS-1101, CAL-101 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614040 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
Drug class | Phosphoinositide 3-kinase inhibitor[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >84%[3] |
Metabolism | Aldehyde oxidase (~70%), CYP3A4 (~30%);[4] UGT1A4 (minor) |
Metabolites | GS-563117 (inactive in vitro) |
Onset of action | Tmax = 1.5 hours |
Elimination half-life | 8.2 hours |
Excretion | Feces (78%), urine (14%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C22H18FN7O |
Molar mass | 415.432 g·mol−1 |
3D model (JSmol) | |
| |
|
Idelalisib, sold under the brand name Zydelig, is a medication used to treat chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL).[3][2] It is used when other treatments have failed or are not appropriate.[3][5] It is taken by mouth.[3]
Common side effects include infection, low white blood cells, diarrhea, liver problems, rash, and fever.[2] Other side effects may include allergic reactions.[3] Use in pregnancy may harm the baby.[3] It is a phosphoinositide 3-kinase inhibitor which blocks PI3Kδ.[1][2]
Idelalisib was approved for medical use in the United States and Europe in 2014.[1][2] In the United Kingdom a month of treatment costs the NHS about £3,100 as of 2021.[5] This amount in the United States costs about 12,300 USD.[6]
References
edit- ^ a b c "Idelalisib Monograph for Professionals". Drugs.com. Archived from the original on 24 October 2020. Retrieved 25 November 2021.
- ^ a b c d e f g "Zydelig EPAR". European Medicines Agency (EMA). Archived from the original on 23 October 2020. Retrieved 21 October 2020.
- ^ a b c d e f g h "Zydelig- idelalisib tablet, film coated". DailyMed. 22 October 2018. Archived from the original on 23 October 2020. Retrieved 21 October 2020.
- ^ "Clinical Pharmacology and Biopharmaceutics Review: Zydelig (idelalisib)" (PDF). U.S. Food and Drug Administration. p. 6. Archived (PDF) from the original on 28 April 2016. Retrieved 15 April 2016.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1029. ISBN 978-0857114105.
- ^ "Zydelig Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 April 2021. Retrieved 25 November 2021.